DEEPLEX, BY GENOSCREEN:
From clinical samples to tuberculosis drug resistance profile
Tuberculosis or TB, is the world’s most lethal infectious disease. This infection is caused by a bacteria called Mycobacterium tuberculosis, which mainly affects the lungs, but it can affect any part of the body.
About one third of the world’s population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with disease.
The treatment of active tuberculosis is based mainly on antibiotics, a therapy that lasts several months. This therapy will be effective only if the TB strains that infect the patient are sensitive to the combination of the antibiotic chosen for the care of the patient.
The three reasons why multidrug resistance continues to emerge and spread are the misdiagnosis, mismanagement of TB treatment and person-to-person transmission.
Multidrug-resistant TB (MDR TB) is caused by TB bacteria that are resistant to at least isoniazid and rifampin, the two most potent TB drugs. These drugs are used to treat all persons with TB disease.
Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
In 2018, an estimated 500 000 people worldwide developed MDR-TB. The countries with the largest numbers of MDR/RR-TB cases were China, India and the Russian Federation. It is estimated that about 6.2% of these cases were XDR-TB.
Deeplex® Myc-TB, is an innovative & integrated culture free solution directly applicable on clinical samples. The product is based on targeted deep sequencing and on automatized data analysis, via a Deeplex® cloud-based software through a secure Web Application.
This innovation kit (or assay) guide the therapeutic management of TB patients in an effective way, by giving a rapid and large screening of genetic resistance to TB drugs.
Deeplex® Myc-TB is an all-in-one test for species-level identification, genotyping and prediction of antibiotic resistance in Mycobacterium tuberculosis complex strains. As the first ever tool to exploit in-depth DNA sequencing technology and thus detect and analyze antibiotic resistance, Deeplex® Myc-TB detects mutations responsible of antituberculosis drugs resistance.
antibiotic molecules in one single analysis
from clinical sample to results
samples analysed simultaneously
mycobacterial loci screened
identifiable mycobacterial species
for any enquirement, kit ordering or demonstration request